Document Classification

Section Type: RESULTS

Text: Symptomatic recurrent venous thromboembolism or death from venous thromboembolism occurred in 73 of the 829 patients (8. 8 %) who were receiving placebo, as compared with 14 of the 840 patients (1. 7 %) who were receiving 2. 5 mg of apixaban (a difference of 7. 2 percentage points ; 95 % confidence interval [CI], 5. 0 to 9. 3) and 14 of the 813 patients (1. 7 %) who were receiving 5 mg of apixaban (a difference of 7. 0 percentage points ; 95 % CI, 4. 9 to 9. 1) (P < 0. 001 for both comparisons).